Drug Profile
PRT 062607
Alternative Names: BIIB-057; P 50515; PRT-2607; PRT062607; Syk inhibitor - BiogenLatest Information Update: 14 Feb 2022
Price :
$50
*
At a glance
- Originator Portola Pharmaceuticals
- Developer Alexion AstraZeneca Rare Disease; Biogen
- Class Antineoplastics; Antirheumatics; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Allergic asthma
- No development reported Cancer; Inflammation; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(In volunteers) in United Kingdom (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(In volunteers) in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in United Kingdom (PO)